In randomized trials, the effects of another FXR agonist, obeticholic acid (OCA), were studied in a group of patients with T2DM and non-alcoholic fatty liver disease (NAFLD) (23 in the placebo group, 20 receiving 25 mg of OCA, and 21 receiving 50 mg of OCA) regarding IS, metabolic parameters and levels of the FGF19 [104]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.